Rectovaginal Fistula Market Research Report: by Diagnosis (Physical Exam, Contrast Tests, Blue Dye Test, Computerized Tomography (CT) Scan) By Treatment (Medications, Surgery) By End User (Hospitals & Clinics, Diagnostic Centers) - Forecast Till 2027
ID: MRFR/HC/5672-HCR | February 2021 | Region: Global | 90 Pages
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Treatment Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Rectovaginal Fistula Market, by Diagnosis
6.1 Introduction
6.2 Physical Exam
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3 Contrast Tests
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4 Blue Dye Test
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.5 Computerized Tomography (CT) Scan
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.6 Magnetic Resonance Imaging (MRI)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.7 Anorectal Ultrasound
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.8 Anorectal Manometry
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.9 Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 7. Global Rectovaginal Fistula Market, by Treatment
7.1 Introduction
7.2 Medications
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.1 Antibiotics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.2 Infliximab
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3 Surgery
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.1 Sewing an Anal Fistula Plug or Patch of Biologic Tissue into the Fistula
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.2 Using a Tissue Graft
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.3 Repairing the Anal Sphincter Muscles
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3.4 Performing a Colostomy before Repairing a Fistula in Complex or Recurrent Cases
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 8. Global Rectovaginal Fistula Market, by End User
8.1 Introduction
8.2 Hospitals & Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3 Diagnostic Centers
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4 Academic Institutions and Research Organizations
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.5 Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 9. Global Rectovaginal Fistula Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
Chapter 11. Company Profiles
11.1 Cook Medical
11.1.1 Company Overview
11.1.2 Diagnosis Overview
11.1.3 Financials Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 Takeda Pharmaceutical Company
11.2.1 Company Overview
11.2.2 Diagnosis Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Johnson & Johnson Services Inc..
11.3.1 Company Overview
11.3.2 Diagnosis Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Pfizer Inc.
11.4.1 Company Overview
11.4.2 Diagnosis Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Allergan
11.5.1 Company Overview
11.5.2 Diagnosis Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 AbbVie Inc
11.6.1 Company Overview
11.6.2 Diagnosis Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Novartis International AG.
11.7.1 Overview
11.7.2 Diagnosis Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Bayer AG
11.8.1 Overview
11.8.2 Diagnosis Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Bristol-Myers Squibb
11.9.1 Overview
11.9.2 Diagnosis Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Boehringer Ingelheim GmbH
11.10.1 Overview
11.10.2 Diagnosis Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Predictions for the Rectovaginal Fistula Industry
Chapter 13. Appendix
LIST OF TABLES
Table 1 Global Rectovaginal Fistula Market Synopsis, 2020-2027
Table 2 Global Rectovaginal Fistula Market Estimates and Forecast, 2020-2027
(USD Million)
Table 3 Global Rectovaginal Fistula Market, by Region, 2020-2027 (USD Million)
Table 4 Global Rectovaginal Fistula Market, by Diagnosis, 2020-2027 (USD Million)
Table 5 Global Rectovaginal Fistula Market, by Treatment, 2020-2027(USD Million)
Table 6 Global Rectovaginal Fistula Market, by End User, 2020-2027 (USD Million)
Table 7 North America: Rectovaginal Fistula Market, by Diagnosis, 2020-2027 (USD Million)
Table 8 North America: Rectovaginal Fistula Market, by Treatment, 2020-2027 (USD Million)
Table 9 North America: Rectovaginal Fistula Market, by End User, 2020-2027 (USD Million)
Table 10 US: Rectovaginal Fistula Market, by Diagnosis, 2020-2027 (USD Million)
Table 11 US: Rectovaginal Fistula Market, by Treatment, 2020-2027 (USD Million)
Table 12 US: Rectovaginal Fistula Market, by End User, 2020-2027 (USD Million)
Table 13 Canada: Rectovaginal Fistula Market,by Diagnosis, 2020-2027 (USD Million)
Table 14 Canada: Rectovaginal Fistula Market, by Treatment, 2020-2027 (USD Million)
Table 15 Canada: Rectovaginal Fistula Market, by End User, 2020-2027 (USD Million)
Table 16 South America: Rectovaginal Fistula Market, by Diagnosis, 2020-2027 (USD
Million)
Table 17 South America: Rectovaginal Fistula Market, by Treatment, 2020-2027 (USD Million)
Table 18 South America: Rectovaginal Fistula Market, by End User, 2020-2027 (USD Million)
Table 19 Europe: Rectovaginal Fistula Market, by Diagnosis, 2020-2027 (USD Million)
Table 20 Europe: Rectovaginal Fistula Market, by Treatment, 2020-2027 (USD Million)
Table 21 Europe: Rectovaginal Fistula Market, by End User, 2020-2027 (USD Million)
Table 22 Western Europe: Rectovaginal Fistula Market, by Diagnosis, 2020-2027 (USD Million)
Table 23 Western Europe: Rectovaginal Fistula Market, by Treatment, 2020-2027 (USD Million)
Table 24 Western Europe: Rectovaginal Fistula Market, by End User, 2020-2027 (USD Million)
Table 25 Eastern Europe: Rectovaginal Fistula Market, by Diagnosis, 2020-2027 (USD Million)
Table 26 Eastern Europe: Rectovaginal Fistula Market, by Treatment, 2020-2027 (USD Million)
Table 27 Eastern Europe: Rectovaginal Fistula Market, by End User, 2020-2027(USD Million)
Table 28 Asia-Pacific: Rectovaginal Fistula Market, by Diagnosis, 2020-2027 (USD Million)
Table 29 Asia-Pacific: Rectovaginal Fistula Market, by Treatment, 2020-2027 (USD Million)
Table 30 Asia-Pacific: Rectovaginal Fistula Market, by End User, 2020-2027 (USD Million)
Table 31 Middle East & Africa: Rectovaginal Fistula Market, by Diagnosis, 2020-2027 (USD Million)
Table 32 Middle East & Africa: Rectovaginal Fistula Market, byTreatment, 2020-2027 (USD Million)
Table 33 Middle East & Africa: Rectovaginal Fistula Market, by End User, 2020-2027 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Rectovaginal Fistula Market
Figure 3 Segmentation Market Dynamics for Global Rectovaginal Fistula Market
Figure 4 Global Rectovaginal Fistula Market Share, by Diagnosis, 2020
Figure 5 Global Rectovaginal Fistula Market Share, by Treatment, 2020
Figure 6 Global Rectovaginal Fistula Market Share, by End User, 2020
Figure 7 Global Rectovaginal Fistula Market Share, by Region, 2020
Figure 8 North America: Rectovaginal Fistula Market Share, by Country, 2020
Figure 9 Europe: Rectovaginal Fistula Market Share, by Country, 2020
Figure 10 Asia-Pacific: Rectovaginal Fistula Market Share, by Country, 2020
Figure 11 Middle East & Africa: Rectovaginal Fistula Market Share, by Country, 2020
Figure 12 Global Rectovaginal Fistula Market: Company Share Analysis, 2020 (%)
Figure 13 Cook Medical : Key Financials
Figure 14 Cook Medical : Segmental Revenue
Figure 15 Cook Medical : Geographical Revenue
Figure 16 Takeda Pharmaceutical Company : Key Financials
Figure 17 Takeda Pharmaceutical Company : Segmental Revenue
Figure 18 Takeda Pharmaceutical Company : Geographical Revenue
Figure 19 Johnson & Johnson Services Inc.. : Key Financials
Figure 20 Johnson & Johnson Services Inc.. : Segmental Revenue
Figure 21 Johnson & Johnson Services Inc.. : Geographical Revenue
Figure 22 Pfizer Inc. : Key Financials
Figure 23 Pfizer Inc. : Segmental Revenue
Figure 24 Pfizer Inc. : Geographical Revenue
Figure 25 Allergan. : Key Financials
Figure 26 Allergan. : Segmental Revenue
Figure 27 Allergan. . Geographical Revenue
Figure 28 AbbVie Inc : Key Financials
Figure 29 AbbVie Inc : Segmental Revenue
Figure 30 AbbVie Inc : Geographical Revenue
Figure 31 Novartis International AG. : Key Financials
Figure 32 Novartis International AG. : Segmental Revenue
Figure 33 Novartis International AG. : Geographical Revenue
Figure 34 Bristol-Myers Squibb : Key Financials
Figure 35 Bristol-Myers Squibb : Segmental Revenue
Figure 36 Bristol-Myers Squibb : Geographical Revenue
Figure 37 Boehringer Ingelheim GmbH : Key Financials
Figure 38 Boehringer Ingelheim GmbH : Segmental Revenue
Figure 39 Boehringer Ingelheim GmbH : Geographical Revenue
Rectovaginal Fistula Market Scenario
Rectovaginal fistula market is expected to grow significantly over the forecast period. The market held a market value of USD 950 million in 2017 and is projected to grow at a CAGR of 5.4% over the forecast period. Rectovaginal fistula is abnormal connection between lower portion of large intestine- rectum-vagina. There are various causes of rectovaginal fistula such as Crohn's disease, cancer or radiation treatment in pelvic area, surgery involving vagina, perineum, rectum or anus, injuries during childbirth, and others.
The factors such as increasing prevalence pelvic cancer, Crohn’s disease is the major driving factors for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer treatment. Furthermore, growing diagnosis methods for rectovaginal fistula will boost the market growth during forecast period.
However, high cost of the surgery may hamper the growth of the market during the forecast period.
According to National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.
Segmentation
The rectovaginal fistula market has been segmented into diagnosis, treatment, and end user.
By diagnosis, the market has been segmented into physical exam, contrast tests, blue dye test, computerized tomography (CT) scan, magnetic resonance imaging (MRI), anorectal ultrasound, anorectal manometry, and others.
Based on treatment, the market has been segmented into medications and surgery. Medications is further segmented into antibiotics and infliximab. Surgery is further segmented into sewing an anal fistula plug or patch of biologic tissue into the fistula, using a tissue graft, repairing the anal sphincter muscles, performing a colostomy before repairing a fistula in complex or recurrent cases.
The rectovaginal fistula market, by end user, has been segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations, and others.
The rectovaginal fistula market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rectovaginal fistula market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European rectovaginal fistula market has been segmented into Western Europe and Eastern Europe. The Western Europe rectovaginal fistula market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The rectovaginal fistula market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rectovaginal fistula market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
Cook Medical, Takeda Pharmaceutical Company, Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc, Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A are some of the prominent players in the rectovaginal fistula market.
Regional Market Summary
Global Rectovaginal Fistula Share (%), by Region, 2017
Source: White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the rectovaginal fistula market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.
Europe is expected to hold the second largest position in the rectovaginal fistula market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).
The rectovaginal fistula market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biotechnology and pharmaceutical sector and growing number of target population in the region.
The Middle East & Africa has the lowest share of the rectovaginal fistula market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.
Market of Rectovaginal Fistula, by Diagnosis:
- Physical Exam
- Contrast Tests
- Blue Dye Test
- Computerized Tomography (CT) Scan
- Magnetic Resonance Imaging (MRI)
- Anorectal Ultrasound
- Anorectal Manometry
- Others
Market of Rectovaginal Fistula, by Treatment:
- Medications
- Antibiotics
- Infliximab
- Surgery
- Sewing an Anal Fistula Plug or Patch of Biologic Tissue into the Fistula
- Using a Tissue Graft
- Repairing the Anal Sphincter Muscles
- Performing a Colostomy before Repairing a Fistula in Complex or Recurrent Cases
Market of Rectovaginal Fistula, by End User:
- Hospitals & Clinics
- Diagnostic Centers
- Academic Institutions and Research Organizations
- Others
Market of Rectovaginal Fistula, by Region:
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
- Middle East
- Africa
Market of Rectovaginal Fistula, by Key Players:
- Cook Medical
- Takeda Pharmaceutical Company
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Allergan
- AbbVie Inc
- Novartis International AG
- Bayer AG
- Bristol-Myers Squibb
- Boehringer Ingelheim GmbH
- Hoffmann-La Roche
- Eli Lilly and Company
- GlaxoSmithKline plc
- Sanofi S.A
- Others
Intended Audience:
- Pharmaceutical and Biotechnological Companies
- Contract Research Organizations
- Academic and Research Institutes
- Government Associations
